Tarsus’ repurposed dog drug headed to FDA after eye drop’s PhIII win

Tarsus Pharmaceuticals will ship its eye drop off to the FDA before year’s end in the hopes of securing the first regulatory nod for a treatment for Demodex blepharitis, or eyelid mange, after a Phase III data drop Monday.

“This is a trial that really hasn’t been conducted by anyone...

Click to view original post